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Abstract
Background: Ulcerative colitis (UC) and Crohn's disease (CD) are characterized by intestinal
inflammation mainly caused by a disturbance in the balance between cytokines and increased
complement (C) activation. Our aim was to evaluate possible associations between C activation
capacity and prednisolone treatment.
Methods: Plasma from patients with exacerbations of UC (n = 18) or CD (n = 18) were collected
before and during high dose prednisolone treatment (1 mg/kg body weight) and tapering.
Friedman's two way analysis of variance, Mann-Whitney U test and Wilcoxon signed-rank sum test
were used
Results:  Before treatment, plasma from CD patients showed significant elevations in all C-
mediated analyses compared to the values obtained from 38 healthy controls (p < 0.02), and in
mannan binding lectin (MBL)-concentration and MBL-C4-activation capacity (AC) values compared
to UC patients (p < 0.02). Before treatment, plasma from UC patients showed significant elevations
only in the classical pathway-mediated C3-AC compared to values obtained from healthy controls
(p < 0.01). After treatment was initiated, significant reductions, which persisted during follow-up,
were observed in the classical pathway-mediated C3-AC and MBL-C4-AC in plasma from CD
patients (p < 0.05).
Conclusion: Our findings indicate that C activation capacity is up-regulated significantly in plasma
from CD patients. The decreases observed after prednisolone treatment reflect a general down-
regulation in immune activation.
Background
The complement (C) system consists of more than 20 pro-
teins and a number of cell associated regulator molecules
and receptors [1]. The C system is activated through either
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of three pathways, initiated by e.g. microorganisms,
immune complexes (IC), and tissue injuries.
The classical pathway (CP) is initiated by IgM and IgG-
molecules, bound to antigens, which trigger the activation
of proenzymes leading to cleavage of C2 and C4, and
eventually to cleavage of C3.
Cleavage of C3 is a key reaction in the C sequence as the
classical and alternative pathways (AP) converge here, and
from this point on potent anaphylactic and chemotactic C
split-products are generated. Alternative pathway activa-
tion is initiated by CP-generated C3b or by a continuous
low 'tick-over' activation of C3, generating C3b which
binds randomly to available cell surfaces. Mannan-bind-
ing lectin (MBL) is the only known collectin known to
activate the C system and binds multivalently to terminal
mannose, N-acetylglucosamine, glucose and fucose on
yeast cells and Gram-negative bacteria, thereby promoting
phagocytosis of the microorganisms without the involve-
ment of antibodies.
The MBL-pathway converges with the CP at the level of C4
which may be activated to generate C4b, which binds ran-
domly to available surfaces. The activity of C, and espe-
cially C3b/iC3b and C4b/iC4b, is strictly regulated by
proteins present ubiquitously in fluid-phases and
expressed on almost all cell surfaces. Further insights into
C continue to emerge, e.g. that MBL utilizes two specific
serine proteases (MASP-1, MASP-2) to initiate the activa-
tion of C, and the function of these proteases may influ-
ence the pathogenesis of more diseases.
A role of the C system in the pathogenesis of ulcerative
colitis (UC) and Crohn's disease (CD), or in maintaining
inflammation, has been established by several observa-
tions: Mucosal cells show a down-regulation in their
expression of C regulators within the affected areas of UC
and CD [2]. A concomitant occurrence of IC and C activa-
tion has been demonstrated in plasma from UC and CD
patients during clinical exacerbations [3-5]. Deposits of
several C components in colonic mucosal are found to
correlate significantly to the degree of inflammation in
UC and CD [6,7]. A putative auto-antigen is demonstrable
in colonic mucosal and in the extraintestinal tissues
affected by UC [7,8], this auto-antigen may trigger C acti-
vation. The C split-product C5a may participate in the for-
mation of the granulomas observed in colonic tissue
affected by CD [9]. Thus, both AP and CP-mediated C acti-
vation have been suggested to be involved in UC and CD
[10].
Glucocorticoids suppress inflammatory processes, e.g. by
down-regulation of the transcription/translation of proin-
flammatory cytokines such as tumor necrosis factor alpha
and interleukin-6 [11], presumeable by an inhibition of
nuclear factor kappa B [12]. The effects of glucocorticoids
on C activation have been reported inconsistently. This is
partly explained by the dependency on the type and dos-
age of glucocorticoid administered, and the biphasic
response in C activation with time after administration
[13]. Glucocorticoids may enhance the synthesis of C1-
inhibitor and interfere with the function of C3 conver-
tases, thereby exerting an anti-complementary effect [14-
16]. Glucocorticoids may inhibit C-mediated chemotaxis
[17].
Measurement of C activation has been impeded by the
complexity, lability and reactivity of the system. The
methods currently in use for routine analyses show rather
low sensitivity, and do normally not differentiate between
the pathways, and the serum concentration of MBL varies
considerably amongst individuals influenced by muta-
tions and polymorphism in the promoter region [18]. We
have standardized two functional assays which measure
the C activation capacity of the classical, alternative and
MBL pathways in vitro as function of incubation time. Our
aim was to evaluate C in plasma before and during high-
dose prednisolone treatment and tapering to analyze for a
possible association between C activation capacity and
treatment.
Methods
Patients with clinical exacerbation of UC (n = 18) or CD
(n = 18), necessitating hospitalization and requiring high-
dose prednisolone to induce remission, were included
consecutively at the Medical Department V, Aarhus Uni-
versity Hospital in the period December 2000 to July
2001. Patients were excluded by the presence of obvious
bacterial infection or acute abdomen.
All patients had a well-established diagnosis of UC or CD
according to clinical, biochemical, endoscopy, his-
topathological criteria, and small bowel follow through.
The group of patients with UC consisted of 6 women and
12 men, median 39 years of age (range 21–78). There
were 12 women and 6 men among the patients with CD,
median 29 years of age (range 18–78).
The disease activity was evaluated clinically by the Harvey-
Bradshaw Index in both UC and CD patients [19]. The UC
patients had a median score of 7 (range 5–19), and CD
patients revealed a median score of 7 (range 3–24). Seven-
teen UC patients had extensive colitis (pancolitis) and 1
left sided colitis. Patients with CD had either colon affec-
tion, small bowel affection, or a combination.
At inclusion, UC patients were treated with combinations
of steroids (rectal enema)(n = 6), 5-aminosalicylic acid (nBMC Gastroenterology 2005, 5:31 http://www.biomedcentral.com/1471-230X/5/31
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= 12), antibiotics (n = 1), whereas 6 patients received no
immunomodulatory medication at all. The CD patients
were treated with combinations of steroids (rectal
enema)(n = 1), 5-aminosalicylic acid (n = 7), azathio-
prine (n = 1), antibiotics (n = 1), whereas 4 patients
received no immunomodulatory medication at all.
All treatments except for rectal steroid enema (except for
1 patient) and antibiotics were continued. The treatment
with prednisolon was started instantly, and administrated
intravenously for the first 3–7 days (1 mg/kg body-
weight), followed by oral administration by day 7 where
the dose were tapered to 40–60 mg/day, and further taper-
ing typically 5 mg/week until 0.
Blood samples were collected from all patients before
high-dose prednisolone treatment was initiated, after 7
days of high-dose prednisolone treatment, after 6 weeks
when the prednisolone dosage was approximately 0.5
mg/kg, and after 12 weeks when prednisolone was
stopped for most patients (except in 6 UC- and 4 CD
patients). The patients still treated with prednisolon after
12 weeks were all well characterized by clinical and/or
biochemical relapse during the last tapering period.
Plasma samples from healthy blood donors (n = 38) from
the Department of Clinical Immunology, Aalborg Hospi-
tal were included as controls. In addition, plasma samples
from some of these donors were heat inactivated at 56°C
for 30 min and used as negative internal controls.
The blood samples were collected in citrate tubes by
venepuncture without stasis, placed on ice for a maximum
of 10 min, and centrifuged at 4°C and 2,000 g for 20 min.
Duplicate blood samples were collected in glass tubes and
allowed to clot at room temperature before centrifuged.
Plasma/serum was withdrawn and stored in aliquots of
0.5 ml at minus 80°C.
Plasma/serum samples were analyzed for alternative- and
classical C pathway mediated factor C3 activation capacity
(C3-AC), mannan-binding lectin (MBL), MBL-C4-AC,
leucocyte count, C-Reactive Protein (CRP) and
orosomucoid.
The AC-derived measurements were performed at the Sur-
gical Gastroenterological Research Unit whereas the MBL-
assay was performed as a routine method at the Depart-
ment of Clinical Immunology, Aalborg Hospital, as
described in details elsewhere [20-22].
C3-AC-assay
The enzyme linked immunosorbent assay (ELISA) meas-
ures plasma derived C3b/iC3b deposition on IC during in
vitro C activation. The activation capacity of the C system
is defined as the amount of C3b/iC3b generated and
bound to the solid-phase IC as a function of incubation
time. The assay differentiates between activation medi-
ated by AP and CP. Briefly, the plasma was diluted 1/5 in
MgEGTA-buffer (10 mM Mg2+ and 10 mM EGTA) when
measuring the AP and 1/200 in CaMg-buffer (0.30 mM
Ca2+ and 1.0 mM Mg2+) when measuring the CP. The AP
is activated at low plasma dilutions only and the CP acti-
vation requires Ca2+. Upon C activation, the generated
C3b molecules bind covalently to the IC and are eventu-
ally degraded to iC3b. Bound C3b/iC3b fragments were
detected by the addition of biotinylated rabbit anti-C3c-
antibodies (Dako, Glostrup, Denmark), avidin alkaline
phosphatase, and para-nitrophenylphosphate as enzyme
substrate. In standard dose response curves the absorb-
ance values for plasma dilutions 1/5 (AP) and 1/200 (CP)
were designated 100%. Plasma from 1 healthy donor was
heat inactivated at 56°C for 30 min, and used as negative
control. Test samples were analyzed in duplicate and the
mean value was converted to 'per cent of the standard'
[20].
A second ELISA measured the plasma concentration of
MBL. Briefly, microplates were coated with anti-MBL-anti-
bodies, plasma was diluted 1/100 in dilution-buffer (6.7
g NaCl, 4.6 g NaH2PO4·2H2O, 1.1 g KH2PO4, 5 mM
EDTA, 200 µl mouse IgG). Bound MBL were detected by
the addition of biotinylated anti-MBL-antibodies, avidin-
peroxidase conjugate, and 1,2-phenylene diamine dihy-
drochloride as enzyme substrate. A plasma standard
diluted 1/25-1/3,200 was included in all plates. Plasma
from 3 healthy donors with high, moderate and low con-
centration of MBL were included as controls. Test samples
were analyzed in duplicate and the mean value was used
in the calculations [21].
The third ELISA measured the plasma derived C4b/iC4b
of the MBL-pathway deposited on mannan during in vitro
C activation. Briefly, microtiter plates were coated with
mannan, and plasma was diluted 1/10 in diluent-buffer
(10 mM tris hydroxy aminomethan, 10 mM CaCl2, 1 M
NaCl, 15 mM NaN3, pH 7.8). The assay does not measure
activation of the AP at the plasma dilution (1/10) used
and the CP was not initiated due to the high NaCl-concen-
tration in the diluent buffer (1 M). Bound C4b/iC4b frag-
ments were detected by the addition of biotinylated rabbit
anti-C4c-antibodies (Dako, Glostrup, Denmark), avidin
alkaline phosphatase, and para-nitrophenylphosphate as
enzyme substrate. A plasma standard diluted 1/5-1/100
was included. Test samples were analyzed in duplicate
and the mean value was converted to 'per cent of the
standard'. Plasma from 2 healthy donors with high and
low MBL-C4-AC were included as controls. Plasma from 1
healthy donor was heat inactivated at 56°C for 30 min,
and used as negative control [22].BMC Gastroenterology 2005, 5:31 http://www.biomedcentral.com/1471-230X/5/31
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The measurements of leucocyte count, CRP, and oroso-
mucoid were performed by routine methods at the
Department of Clinical Chemistry, Aarhus University
Hospital.
Ethics
This investigation has been approved by the regional Eth-
ical Committees of Northern Jutland and Aarhus Coun-
ties, and wasin accordance with the standards of the
Declaration of Helsinki II.
Statistics
Non-parametric descriptive (median – range) and com-
parative statistics were used with a probality value of <
0.05 considered statistically significant. Data were ana-
lyzed by non-parametric methods. The calculations and
analyses were performed with Prism 3.0 (GraphPad Soft-
ware Inc., Microsoft Corp., USA). First, overall compari-
son over time (before treatment, 1 week, 6 weeks and 12
weeks after treatment) of a variable in the same group of
patients (e.g. CD patients) was done by Friedman's two-
way analysis. Secondly, paired comparison in a group of
patients of a variable between two different time points
(matched pair) were by Wilcoxon signed-rank test. Fur-
thermore, the Mann-Whitney U test was used comparing
one variable between two different groups at a specific
time point (e.g. plasma value of MBL before prednisolone
treatment in CD patients versus UC patients). Correlation
between two variables were calculated using Spearman's
rank correlation coefficient rho. Finally, to allow for mul-
tiple comparisons the Bonferroni correction was used, the
corrected p-values are stated.
Results
All C data showed a significant variation over time (before
and 1, 6 and 12 weeks after initiation of high dose pred-
nisolone treatment) in both UC and CD patients (in both
groups: p < 0.0001, Friedman's test).
Table 1 shows the C-activation
Before treatment
Plasma from CD patients revealed significant elevations
in the activating capacity of all C pathways compared to
the values obtained from healthy controls (p < 0.02,
Mann-Whitney test). In plasma from UC patients, only
the median classical pathway-mediated C3-AC was signif-
icantly elevated compared to the values obtained from
healthy controls (p < 0.01, Mann-Whitney test). Plasma
from CD patients revealed significant elevations in MBL-
concentration and MBL-C4-AC values compared to the
values obtained from UC patients (p < 0.02, Mann-Whit-
ney test). No significant difference was observed in the
alternative or classical pathway-mediated C3-AC between
the patient groups.
Table 1: Complement activation in plasma from patients with Crohn's disease (CD), patients with ulcerative colitis (UC) and healthy 
subjects (HS) before and after 1, 6 and 12 weeks high-dose treatment with prednisolone.
before treatment after 1 week after 6 weeks after 12 weeks
Number of patients Number of patients Number of patients Number of patients
CD 18 18 18 18
UC 18 18 18 16
HS 38 -- -- --
C3-AC, alternative % of standard % of standard % of standard % of standard
CD 61.5 (53–82) 51.5 (49–71) 55.5 (49–70) 59 (49–75)
UC 58 (49–78) 49 (49–70) 49 (49–78) 59 (49–70)
HS 49 (49–67) -- -- --
C3-AC, classical % of standard % of standard % of standard % of standard
CD 109 (81–172) 97.5 (39–124) 94.5 (70–141) 99.5 (53–143)
UC 97 (39–148) 88 (58–129) 91 (59–115) 94 (39–160)
HS 82.5 (68–108) -- -- --
MBL-concentration ng/ml ng/ml ng/ml ng/ml
CD 3251 (14 – 6085) 3071 (10 – 4636) 2911 (10 – 5178) 3257 (10 – 4718)
UC 1082 (6 – 3926) 1171 (3 – 4845) 1141 (3 – 4590) 1292 (3 – 4147)
HS 1219 (2 – 3577) -- -- --
MBL-C4-AC % of standard % of standard % of standard % of standard
CD 118 (21–187) 63 (25–192) 62.5 (21–163) 87 (17–192)
UC 54 (12–201) 54 (11–192) 45 (9–163) 55 (12–192)
HS 66.5 (9–162) -- -- --
Median and range (in parenthesis) of alternative and classical pathway-mediated C3-activation capacity(C3-AC), mannan-binding lectin (MBL) 
concentration, MBL-C4-AC.BMC Gastroenterology 2005, 5:31 http://www.biomedcentral.com/1471-230X/5/31
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After treatment
No significant difference was observed neither in the alter-
native nor in the classical pathway-mediated C3-AC
between the patient groups. The MBL-concentration and
MBL-C4-AC values obtained were significantly higher at
week 6 and 12 in plasma from CD patients compared to
UC patients (p < 0.04, Mann-Whitney test).
In CD patients
The classical pathway-mediated C3-AC and MBL-C4-AC
remained significantly reduced over time in plasma from
CD patients (p < 0.05, Wilcoxon test). In UC patients: No
significant difference over time was observed.
Other parameters
The medians of leucocyte count, CRP, and orosomucoid
which were obtained from blood/plasma of CD and UC
patients are stated in Table 2. Before treatment, plasma
from CD patients revealed significant elevations in CRP
and orosomucoid (p < 0.04, Mann-Whitney test). After
treatment, the medians of all parameters were
comparable.
The degrees of correlation were calculated for all C-values
against CRP, orosomucoid, leucocyte count, and the Har-
vey-Bradshaw index, respectively. No signification corre-
lation was observed
Discussion
Our findings indicate that C activation capacity is up-reg-
u l a t e d  i n  p l a s m a  f r o m  C D  p a t i e n t s  c o m p a r e d  t o  b o t h
healthy controls and UC patients, and that the decreases
observed after treatment with prednisolone reflect a gen-
eral down-regulation in immune activation as indicated
by the concomitant trends in CRP and orosomucoid. The
initial increase in leucocyte count may reflect a mobiliza-
tion of premature leucocytes from the bone marrow. The
demonstrated association between C activation capacity
and treatment with prednisolone seems to support the
finding that glucocorticoids may interfere with C activa-
tion capacity [13-16]. However, the concentrations of C
components in plasma depend on a complex balance, e.g.
between synthesis and degradation rates, and degree of
binding to other proteins.
The C system has been suggested to be involved in the
pathogeneses of UC and CD, although differently. Thus, a
putative auto-antigen, with a potential to initiate the clas-
sical pathway, is demonstrable in tissues affected by UC
[7,8], whereas C activation may occur through the alterna-
tive pathway in patients with CD [10]. The lectin-medi-
ated C activation has not been considered in earlier
studies of this topic.
More clinical features differ between UC and CD. Thus,
UC is characterized by inflammatory infiltrations within
the mucosa of the colon and rectum, whereas the infiltra-
tions in CD may affect all layers of the intestinal wall. The
clinical exacerbations, frequently necessitating hospitali-
zation and glucocorticoid treatment, may vary widely
between UC and CD, and by the duration of disease.
These variations in clinical features may not be detectable
with the Harvey-Bradshaw index.
Our results show more differences in plasma derived C
activation capacity between patients with UC and CD,
which is in concordance with the overall immune activa-
tion as indicated by CRP, orosomucoid and leucocyte
count, and by the fact that CRP may activate C by
initiating the classical pathway [23]. The up-regulation in
C activation capacity is more pronounced in plasma from
Table 2: Acute phase reactants (median values) in plasma/blood from patients with Crohn's disease (CD), patients with ulcerative 
colitis (UC) before and after 1,6 and 12 weeks high-dose treatement with prednisolone.
before treatment after 1 week after 6 weeks after 12 weeks
C Reactive Protein
(nmol/L)
CD 372 47 47 62.5
UC 47 47 47 33.5
Orosomucoid
(µmol/L)
CD 39 33 28 25
UC 25 25 20 24
Leucocyte count
(109/L)
CD 10.9 13.5 9.7 8.1
UC 8.3 13.6 8.6 7.9BMC Gastroenterology 2005, 5:31 http://www.biomedcentral.com/1471-230X/5/31
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CD-patients compared to UC, in accordance with in vitro
studies [24,25].
The demonstrated reduction of MBL-concentration and
MBL-C4-AC in plasma from UC patients before treatment,
compared to values obtained from either healthy controls
or CD patients, is unexpected. Thus, the MBL gene vari-
ants, correlating with reduced MBL concentrations, occur
less frequently in UC patients compared to CD patients
and healthy controls [26]. However, our finding may be
secondary to the use of immunomodulators at study
entry, which was administered more frequently to the UC
patients, or to differences in clinical features between UC
and CD.
The significantly increased MBL-concentration and MBL-
C4-AC values in plasma from CD patients, compared to
values obtained from healthy controls, are opposite to our
results in plasma from CD patients complicated by fistu-
lizing ano-rectal disease [27] despite their comparability
in disease activity as indicated by the Harvey-Bradshaw
values. The discrepancy in MBL-concentration and MBL-
C4-AC values of these two groups of CD-patients may be
due to the circumstance that the patients with fistulizing
disease were highly selected as chronic out-patients with a
low degree of inflammation as indicated by CRP. In the
present study only one of the CD patients had fistulizing
ano-rectal disease.
The demonstrated association between C activation
capacity and treatment with prednisolone seems to reflect
a treatment-induced down-regulation in inflammation, as
estimated by CRP and orosomucoid.
Conclusion
We found that C activation capacity is up-regulated in
plasma from CD patients compared to UC patients and
healthy controls. The plasma MBL-concentration and
MBL-mediated C activation capacity were reduced in UC
patients compared to healthy controls. The changes in C
activation capacity during prednisolone treatment seems
to reflect a general down regulation in immune activation
especially in CD patients.
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